Takeda Signs US$1.13 B Deal with Hutchmed for Colorectal Cancer Drug

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 2 (Table of Contents)

Published: 1 Feb-2023

DOI: 10.3833/pdr.v2023.i2.2761     ISSN: 1756-7874

Section: Licensing



In an attempt to bolster its oncology pipeline, Takeda has paid Hutchmed US$400 M upfront and committed up to US$730 M more for the further development and commercialisation of fruquintinib outside of mainland China, Hong Kong and Macau...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details